Back to all studies
RecruitingNCT05803551

A Study of Ketamine Infusions to Treat Clinically-depressed ICU Patients

This recruiting study focuses on depression and currently lists sites or participation links in United States.

DepressionOtherFrom 18 Years to 99 Years
In plain English

Key information made simple

This study exists to explore whether the medication Ketamine could improve care and understanding. For people living with Depression, that matters because care needs to work in daily life, not just in theory. The findings could guide better understanding and future care, and taking part helps build that evidence for others.

What to expect

Your next step

The official record suggests in-person participation through a clinic, with sites including Mayo Clinic Florida in Jacksonville. Participation appears to involve a study treatment together with follow-up visits and routine safety or progress checks. The main fit is usually meeting the main study requirements, while common reasons not to take part include pregnancy or breastfeeding and active substance or alcohol problems that could affect the results. This is an early-stage study, which usually means a smaller group and a focus on learning how the approach behaves.

Official source

Registry reference

This page links back to the public source record so people can verify details directly with the registry and research team.

If you want the full study description, eligibility criteria, locations, and sponsor information in the original format, this is the place to check before taking the next step.

Open source record
Interested?

Check my eligibility

Study reference: NCT05803551. Your email is the only field you need to provide here.
In practice

For you

Taking part may give access to a new approach being evaluated.

It requires regular visits and structured follow-up.

Requires travel, with in-person participation in United States.

Important

Not medical advice

Information from public sources. Are you the study sponsor? Contact us to update this page: hi@hopestage.com